MIRA Pharma (MIRA) - מכפיל P/S עתידי
MIRA Pharmaceuticals is developing the MIRA-55 synthetic cannabinoid ecosystem by creating closed treatment protocols. The company adheres to ESG standards for emission filtration and research ethics, targeting the growing demand for non-opioid analgesics. The current forward P/S ratio helps filter out market noise, while the value represents the current valuation metric for expected sales one year forward.
פילוחי מדדים מקיפים ואנליטיקה עבור MIRA Pharmaceuticals, Inc. (MIRA)
The selection of defensive assets is based on a business's ability to generate revenue amid rising borrowing costs. For MIRA Pharmaceuticals (MIRA), given its high preclinical research expenditures and the risk of testing delays, the forward P/S trend reflects the market valuation of future sales per share. This indicator measures capital's willingness to invest in the company's expected earnings, signaling the stock's sensitivity to operational shocks.
